News|Videos|December 18, 2023
Adverse Events Seen With Systemic Therapies in Patients With Advanced Endometrial Cancer
Drs Backes and Powell discuss the management of adverse events between upfront immunotherapy versus chemotherapy followed by later immunotherapy for endometrial cancer, noting the need for molecular subgroup data from trials like LEAP-001.
Advertisement
Episodes in this series
Advertisement
Related to this article
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL
5